Metabolic Profiling of Inflammatory Bowel Disease in Children and Adolescents

Metabolic Profiling of Inflammatory Bowel Disease in Children and Adolescents - MetabIBD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030960

Enrollment

200

Registered

2022-12-19

Start date

2022-09-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50 K51 K52

Interventions

Group 1: Pediatric IBD patients receiving Infliximab - Observational group, longitudinal measurement of the metabolome in different biofluids. Group 2: Pediatric IBD patients receiving Adalimumab - Ob

Eligibility

Sex/Gender

All

Age

No minimum to 20 Years

Inclusion criteria

Inclusion criteria: none

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Establishment of specific metabolic profiles for diagnosis and activity monitoring in IBD patients	—

Secondary

Measure	Time frame
Establishment of specific metabolic profiles for side effects and development of anti drug antibodies	—

Countries

Germany

Contacts

Public ContactMoritz Niesert

Universitätsklinikum Heidelberg, Klinik für Kinderheilkunde I

Moritz.Niesert@med.uni-heidelberg.de+49 6221 56 4002

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026